CymaBay Appears Stronger Threat To Ocaliva In PBC Than Ipsen/Genfit

 
• By Joseph Haas
2023 AASLD
PPAR agonists from Genfit and CymaBay are battling for a second-line indication in PBC • Source: Scrip

More from Strategy

More from Business